A majority of genetic variants associated with congenital heart disease (CHD) are located within noncoding regions likely to be gene regulatory regions. Therefore, functional validation of enhancers driving expression of CHD relevant genes will lay the groundwork for understanding potentially deleterious variants (PDVs). Enhancers drive tissue specific expression, and cardiovascular (CV) enhancers are poorly conserved between humans and other species. Therefore, it is important to define enhancer function in defined human CV lineages. The hypothesis of our Main Project is that enhancers operate dynamically in a temporal and/or lineage specific manner during cardiomyocyte (CM) specification, and that mutation of enhancers driving expression of CHD relevant genes will disrupt CM lineage development.
Aims are: 1) To investigate the transcriptional profile and genome-wide epigenetic landscape of human ventricular and atrial CM lineages during development; 2) To investigate enhancer-promoter interactions that regulate ventricular and atrial gene programs; 3) To examine effects of enhancer mutation on expression of cognate CHD relevant transcription factors and CM lineage development in vitro and in vivo. The Main Project will provide a CV epigenomic regulatory framework for interrogation of PDVs in noncoding regions, as proposed in the Collaborative Project. The hypothesis of our Collaborative Project is that many genetically unexplained CHDs will be due to PDVs which are located in non-coding sequences and perturb target gene expression by altering functions of cis-regulatory elements, thus leading to an overall disruption of pathways critical for normal cardiac lineage development.
Aims are: 1) To identify a comprehensive set of candidate CHD non-coding PDVs through systematic analysis of Pediatric Cardiac Genetics Center (PCGC) CHD Whole Genomic Sequencing studies with Cardiovascular Development Center (CvDC) lineage specific human epigenomic datasets; 2) To investigate whether candidate CHD non-coding variants perturb enhancer activity using multiple highthroughput in vitro assays; 3) To investigate the functional significance of high confidence regulatory CHD variants in vitro and in vivo.
All aims will utilize hESC models of CV lineage differentiation, and Aim 3 of each project will additionally utilize mouse models. We will establish pipelines of genomewide and highthroughput functional assays, many available through a UCSD Genomics Core. Results will be compared to patient data to investigate congruence of biochemical and morphological/physiological phenotypes. These studies represent collaboration between multiple PIs of complementary expertise, including members of the CvDC and the PCGC (see attached letters), representing an ideal training environment for junior scientists in collaborativ science. Results will result in comprehensive definition of human enhancers dynamically active during differentiation of distinct CV lineages, and will identify variants within these enhancers which contribute to CHD, on a scale made possible only recently by state-of-the-art genomics technologies.

Public Health Relevance

Whole genomic sequencing and genome-wide association studies have revealed genetic sequence variants in non-coding regions of patient DNA that might cause congenital heart disease (CHD). In these studies, we will investigate how these genetic variants might change the cardiovascular genomic regulatory network to cause CHD. This understanding will help us develop better diagnostics and treatments for CHD. (End of Abstract)

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
1UM1HL128773-01
Application #
8953011
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Schramm, Charlene A
Project Start
2015-08-01
Project End
2020-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Veevers, Jennifer; Farah, Elie N; Corselli, Mirko et al. (2018) Cell-Surface Marker Signature for Enrichment of Ventricular Cardiomyocytes Derived from Human Embryonic Stem Cells. Stem Cell Reports 11:828-841
Stroud, Matthew J; Fang, Xi; Zhang, Jianlin et al. (2018) Luma is not essential for murine cardiac development and function. Cardiovasc Res 114:378-388
Yu, Miao; Ren, Bing (2017) The Three-Dimensional Organization of Mammalian Genomes. Annu Rev Cell Dev Biol 33:265-289
Hirai, Maretoshi; Arita, Yoh; McGlade, C Jane et al. (2017) Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 127:569-582
Pradhan, Arjana; Zeng, Xin-Xin I; Sidhwani, Pragya et al. (2017) FGF signaling enforces cardiac chamber identity in the developing ventricle. Development 144:1328-1338
Panopoulos, Athanasia D; D'Antonio, Matteo; Benaglio, Paola et al. (2017) iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports 8:1086-1100
van Vliet, Patrick P; Lin, Lizhu; Boogerd, Cornelis J et al. (2017) Tissue specific requirements for WNT11 in developing outflow tract and dorsal mesenchymal protrusion. Dev Biol 429:249-259
Han, Peidong; Bloomekatz, Joshua; Ren, Jie et al. (2016) Coordinating cardiomyocyte interactions to direct ventricular chamber morphogenesis. Nature 534:700-4
Hirai, Maretoshi; Chen, Ju; Evans, Sylvia M (2016) Tissue-Specific Cell Cycle Indicator Reveals Unexpected Findings for Cardiac Myocyte Proliferation. Circ Res 118:20-8
Boogerd, Cornelis J; Aneas, Ivy; Sakabe, Noboru et al. (2016) Probing chromatin landscape reveals roles of endocardial TBX20 in septation. J Clin Invest 126:3023-35

Showing the most recent 10 out of 12 publications